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Caffeine is the most commonly consumed drug in the world. Although its effects are 
relatively mild when consumed in moderate amounts, there exist cases where caffeine use 
is problematic. Currently no behavioral intervention for problematic caffeine 
consumption exists in which caffeine use is verified beyond self-reports. No measures of 
caffeine dependence and withdrawal exist either. The current study examined the 
viability of contingency management, an empirically supported behavioral intervention 
for reducing drug use, for initiating abstinence from caffeine consumption among college 
students of varying levels of use, as well as validity evidence for novel measures of 
caffeine dependence and withdrawal. Participants (N = 39) came in to the lab for 3 
experimental sessions in an ABA design over the course of 5 to 7 days to complete the 
AUTOC, CWS, and SCEWS and to provide saliva samples. During the BAT participants 
could earn a higher magnitude reward ($20) for abstaining from caffeine. 95% of 
participants met criteria for abstinence during the BAT. The ELISA appeared to work at 
an aggregate level, though individual samples were inconsistent enough to prevent these 
results from being used as a criterion for caffeine abstinence. AUTOC, CWS, and 
SCEWS scores functioned moderately well for measuring caffeine dependence and 
withdrawal. These results indicate CM of caffeine use may be effective for intervening 






Caffeine is a stimulant and the most consumed psychoactive drug in the world. 
Up to 80% of adults in the United States consume caffeine on a daily basis (Julien, 2008). 
Average daily caffeine intake among caffeine consumers has been estimated to be around 
280 mg (Gilbert, 1984). Caffeine consumption typically occurs relatively consistently 
throughout the span of a lifetime; however little is known about its long term effects 
(James, 2004). It is naturally occurring in many foods and drinks commonly consumed in 
western culture, including coffee, tea, and cocoa (i.e., chocolate). Similarly, caffeine is 
added to a variety of consumable items such as soft drinks, energy drinks, gum, and soap, 
and is included as an ingredient in various over the counter and prescription drugs. In the 
United States caffeine is most frequently consumed in coffee and soda (Hughes & 
Oliveto, 1997). 
Caffeine reaches peak blood concentration in 30 to 45 min. Caffeine’s half-life 
varies as a function of individual factors, ranging from 2.5 to 10 hr, and it is longer for 
infants, pregnant women, and elderly persons (Julien, 2008). Once in the bloodstream, 
caffeine exerts excitatory effects as an adenosine antagonist. Adenosine is thought to 
build up during wakefulness, ultimately contributing to feelings of fatigue. By blocking 
adenosine receptors, caffeine causes an alleviation of sleepiness (Carlson, 2011).  
Caffeine consumption, at both high and low doses, has been associated with 
increased alertness if consumed during low levels of arousal (e.g., early morning; 
Nawrot, Eastwood, Rotstein, Hugenholtz, & Feeley, 2003). Wesensten, Killgore, and 
Balkin (2005) demonstrated that a single large dose of caffeine (600 mg) administered to 





vigilance task. Similarly, Smith (2009) showed that a single administration of chewing 
gum containing a small amount of caffeine (40 mg) to college students (N = 118) led to 
significantly better performance on reaction tasks compared to those who consumed 
regular chewing gum or no gum. 
Other subjective effects of caffeine are not as clearly established. For example, 
regular caffeine consumers may demonstrate greater improvements in memory and 
visiospatial reasoning (Jarvis, 1993; Smith, Sturgess, & Gallagher, 1999), although some 
research has shown caffeine to have no effect on memory or even negative effects (e.g., 
Erikson et al., 1985; Terry and Phifer, 1986). Not surprisingly Goldstein, Kaizer, and 
Warren (1965) found that self-reported effects of caffeine on alertness task performance 
did not correlate with actual performance, indicating that subjective self-reports of 
caffeine’s affects may not be valid indicators of the actual behavioral effects of the drug. 
As such, subjective effects of caffeine have also been examined independently of 
behavioral effects. Because many people have experience with caffeine and its effects, 
there is often an expectancy effect associated with the drug. Oei and Hartley (2005) told 
participants they would be consuming caffeine or placebo prior to actually consuming 
one of either caffeinated or decaffeinated coffee. Participants who were told they had 
consumed caffeine made more correct detections in a signal detection task than those 
participants who were told they had consumed placebo, regardless of what they actually 
consumed.  
Most desirable effects of caffeine (e.g., increased alertness) occur following 
consumption of small doses (e.g., less than 200 mg). Consuming larger quantities of 





adverse symptoms, including nervousness and anxiety (Strain, Mumford, Silverman, & 
Griffiths, 1994). Research has suggested that administration of larger doses of caffeine 
(e.g., greater than 200 mg) is associated with increased anger and decreased drowsiness 
(Roache & Griffiths, 1987), although others have found no effect (Swift & Tiplady, 
1988). Likewise, research shows that large doses (e.g., 1 g; Nawrot et al., 2003) of 
caffeine can produce anxiety in adults with anxiety disorders (Nawrot et al., 2003; Bruce, 
Scott, Shine, & Lader, 1982). Caffeine is also related to an increase in time taken to fall 
asleep as well as overall duration of sleep (Brenesova, Oswald, & Loudon, 1975). 
Most research has focused on the acute effects of caffeine however there are some 
notable findings related to the long-term effects of caffeine consumption. Caffeine is 
associated with an increase in occurrence of reproductive complications when consumed 
in doses of 400 mg or more daily during pregnancy (e.g., SIDS; Ford et al., 1998), as well 
as with accelerated decrease in bone density among post-menopausal women who 
consume more than 450 mg daily (Harris & Dawson-Hughes, 1994). There is also an 
established relation between regular caffeine consumption and elevated blood pressure 
(James, 2004). At the population level, any increases in high blood pressure (including 
those attributed to regular caffeine consumption) are usually associated with increased 
rates of cardiovascular disease (James, 2004), though the link between regular caffeine 
consumption and cardiovascular disease is unknown. Additionally, long-term caffeine 
use may lead to a dependence syndrome analogous to other substance use disorders 
described in the DSM-IV-TR (APA, 2000). Although not formally recognized in the 
DSM-IV-TR as a substance of abuse, caffeine can lead to intoxication, withdrawal, and 





intoxication (also referred to as caffeinism; Greden, 1974) include exaggerated 
experience of caffeine withdrawal effects, including nervousness, irritability, agitation, 
and headache (Greden, 1974). Rates of excessive caffeine use leading to intoxication 
among psychiatric inpatients may be as high as 40% (MacKay & Rollins, 1989); 
however, rates of caffeinism in the population are uncertain due to underdiagnoses 
(Greden, 1974).  
Caffeine dependence and withdrawal 
 According to the DSM-IV-TR, drug use must meet at least three of the following 
seven criteria to be considered drug dependence (relevant examples with caffeine 
included in parentheses): (a) tolerance (Griffiths & Woodson, 1988); (b) withdrawal 
(Silverman, Evans, Strain, & Griffiths, 1992); (c) substance often taken in larger amounts 
over a longer period of time than intended (Greden, 1974); (d) persistent desire or 
unsuccessful efforts to cut down or control use (Greden, 1974); (e) a great deal of time 
spent in activities necessary to obtain, use, or recover from the effects of the substance 
(Strain et al., 1994); (f) important social, occupational, or recreational activities given up 
or reduced because of substance use; (g) continued use despite knowledge of a permanent 
or recurrent physical or psychological problem that is likely to have been caused or 
exacerbated by substance use (Greden et al., 1978). Data have shown that caffeine use 
can lead to a situation in which an individual meets criteria for dependence (Hughes, 
Oliveto, Liguori, Carpenter, & Howard, 1998). 
 Caffeine dependence has been scarcely studied explicitly but research has yielded 
data that support the notion that dependence can and does occur. Several efforts have 





Silverman, and Griffiths (1994) examined 99 adults who self-reported psychological and 
physical dependence on caffeine. The authors used a structured clinical interview that 
included assessment of caffeine dependence based on DSM-IV (APA, 1994) criteria for 
substance dependence. Strain et al. (1994) found that 16 participants met criteria for 
caffeine dependence. Hughes, Oliveto, Liguori, Carpenter, and Howard (1998) reported 
prevalence of caffeine dependence criteria among a sample of 162 caffeine users via 
telephone interviews. Using DSM-IV criteria for substance dependence, Hughes et al. 
(1998) found a substantial proportion of participants self-reported experiences consistent 
with meeting criteria for caffeine dependence. Taken together with Strain et al. (1994) 
and other research on the potential for caffeine abuse (e.g., Ogawa & Ueki, 2007; 
Bernstein, Carroll, Thuras, Cosgrove, & Roth, 2002), these results provide compelling 
evidence for caffeine dependence.  
An aspect of dependence that is of particular interest with respect to caffeine is 
withdrawal (e.g., Juliano & Griffiths, 2004). The greatest occurrence of undesirable 
effects of caffeine consumption occurs following cessation of use. Indeed, the effects of 
caffeine vary by latency since last consumption (Yeomans et al., 2002; Addicott & 
Laurienti, 2009; Christopher, Sutherland, & Smith, 2005), suggesting that many of the 
appetitive effects of caffeine are due to relief of caffeine withdrawal. Onset of withdrawal 
symptoms varies but generally occurs around 12 hr after last caffeine consumption 
(Griffiths & Woodson, 1988), with peak intensity of withdrawal symptoms occurring at 
20 to 50 hr after last consumption (Juliano & Griffiths, 2004), continuing with 
progressively severity for 2 to 9 days (McKim, 2007). Symptoms are quickly alleviated 





Juliano and Griffiths (2004) conducted a comprehensive review of the literature 
on caffeine withdrawal and found that headache was the most common symptom of 
withdrawal. Fatigue, decreased energy and activity, decreased alertness, drowsiness, 
decreased well-being, depressed mood, decreased concentration, irritability, and 
fogginess also met the authors’ criteria for valid symptoms of caffeine withdrawal.  
 Despite evidence for caffeine dependence and withdrawal, there currently exists 
no standardized method for measuring these phenomena. Taken together, their lack of 
specific inclusion in the DSM-IV-TR (APA, 2000) and the fact that caffeine is a legal, 
widely available drug, among other potential reasons, limit the perceived prevalence and 
importance of caffeine dependence and withdrawal syndromes.  
Contingency management 
Just as there are few tools for measuring and characterizing caffeine dependence 
and withdrawal, there are fewer available treatment options, presumably because of a 
relative lack of concern related to excessive caffeine consumption. Unlike many other 
types of drugs (e.g., opioids, nicotine, alcohol) there are currently no effective 
pharmacotherapies for stimulants, including caffeine. As such, treatment of problematic 
caffeine consumption (e.g., dependence) may be best approached similarly to how 
dependence for other stimulants is treated—with behavioral interventions. Behavioral 
interventions involve manipulation of environmental variables that influence drug use, 
such as drug cost or availability (Bickel, Madden, & Petry, 1998), in order to decrease or 
cease drug consumption.  
Contingency management (CM) has been a well-studied behavioral intervention 





(e.g., money, prizes) contingent upon providing evidence of reduction or abstention from 
substance use. A wide range of studies have demonstrated the feasibility of CM for 
reducing use of a variety of substances (Petry, 2000), including nicotine (Roll, Higgins, 
& Badger, 1996), cocaine (Silverman, Chutuape, Bigelow, & Stitzer, 1999), opiates 
(Higgins, Stitzer, Bigelow, & Liebson, 1986), methadone (Iguchi, Belding, Morral, & 
Lamb, 1997), alcohol (Miller, Hersen, Eisler, & Watt, 1974), marijuana (Budney, Moore, 
Higgins, & Rocha, 2006), and benzodiazepines (Stitzer, Bigelow, Liebson, & Hawthorne, 
1982).  
Recent meta-analyses support the efficacy of CM and suggest that the effect sizes 
for CM interventions consistently exceed other treatment options for substance 
intervention (i.e., Lussier, Heil, Mongeon, Badger, & Higgins, 2006; Prendergast, Podus, 
Finney, Greenwell, & Roll, 2006; Dutra et al., 2008). Few studies to date have examined 
the efficacy of CM for intervening with caffeine use. 
Several studies have applied CM to caffeine use; however, there are several 
critical deficits that suggest a need for further study. Foxx and Rubinoff (1979) 
investigated the utility of an incentive-based behavioral procedure for reducing excessive 
coffee drinking among three normal-functioning adults who self-reported interest in 
reducing their coffee drinking and consuming at least eight cups of brewed coffee per 
day. A changing criterion design (Hartmann & Hall, 1976) was implemented to reduce 
caffeine consumption to the equivalent of five cups of coffee or fewer over the course of 
4 weeks. Coffee drinking was monitored via participant self-report and self-reports from 
a significant other who frequently interacted with the participant and was familiar with 





drinking to moderate levels of use: Two participants never exceeded criterion levels of 
caffeine consumption and the third participant only exceeded criterion on 2 days (Foxx & 
Rubinoff, 1979). Follow-up at 40 months indicated participants continued to consume 
fewer than the terminal criterion goal of the initial study (Foxx, 1982). Bernard, 
Dennehy, and Keefauver (1981) performed a systematic replication of Foxx and Rubinoff 
(1979) in a single-case research procedure and yielded similar results. Although 
seemingly compelling, caffeine consumption was not verified beyond self-report, a key 
component of CM. 
James, Stirling, and Hampton (1985) studied 27 adults who consumed at least 
eight cups of coffee or tea daily. Participants provided self-reports of caffeine 
consumption supplemented by independent reports of caffeine consumption by 
significant others. Participants were assigned to either a self-initiation regimen (i.e., an 
active treatment control group) or a fading procedure, with criterion determined based on 
individual levels of consumption. Participants in the fading group reduced consumption 
the most from baseline and maintained lowest consumption levels throughout treatment 
and again at 6- and 18-week follow-up.  
CM procedures are effective for initiating and maintaining reduced caffeine 
consumption (Foxx & Rubinoff, 1979; Bernard et al., 1981; James et al., 1985). 
However, findings from studies to date are significantly limited in their reliance on self-
report for verification of meeting criterion levels of caffeine use and lack of verification 
of caffeine use or abstinence. Additionally, CM can be costly to implement in terms of 





The brief abstinence test 
A brief abstinence test (BAT) can be used to model CM and to induce abstinence 
for a short period of time in effort to examine potential for efficacy (Robles et al., 2000). 
Participants in a BAT receive high-magnitude incentives contingent on providing 
evidence (self-report and biological samples) of brief (i.e., hours, or days) drug 
abstinence. Further, the BAT allows for experimental manipulation of use such that 
abstinence and related phenomena, such as withdrawal, may be examined.  As such, a 
BAT is an ideal method for preliminary analysis of the potential efficacy of CM for 
caffeine use. The BAT has been used to initiate abstinence from opiates among opiate 
and cocaine dependent community adults (Sigmon, Correia, & Stitzer, 2004; Robles et 
al., 2000) as well as among nicotine dependent college student smokers (Irons & Correia, 
2008). 
Robles et al. (2000) evaluated the effectiveness of brief abstinence test for cocaine 
among cocaine-dependent methadone maintenance outpatients. Seventy-two participants 
enrolled in a 13-week methadone maintenance program were informed at the beginning 
of week 9 that if they returned in 2 days and had abstained from cocaine use since the 
beginning of the week that they would earn a $100 voucher. Participants who met 
abstinence criteria received payment 2 days after providing urine samples for analysis. 
No new use of cocaine was assumed by either a low benzoyclecgonine concentration 
(i.e., ≤ 300 ng/ml) analyzed from a frozen urine sample or a minimum 50% reduction in 
benzoyclecgonine concentration in the sample. Among those participants with complete 
data sets (n = 50), abstinence during BAT (84%) was significantly greater than abstinence 





combining a high value reinforcer ($100) with a low cost behavioral requirement (i.e., 
abstinence from cocaine use for 2 days) yielded clinically significant rates of substance 
abstinence, particularly when compared to abstinence rates prior to and following the 
intervention. These results provide evidence for the utility of a brief abstinence 
reinforcement procedure for reliably initiating drug abstinence. 
Katz et al. (2002) obtained results similar to Robles et al. (2000) that 
demonstrated the utility of a BAT. They extended the findings of Robles et al. (2000) via 
systematic replication and by introducing two new payment conditions, each of which 
included subsequent payments for additional periods of brief drug abstinence. Katz et al. 
(2000) used a within-subjects design in which participants experienced one of four 
conditions in counterbalanced order, each separated by 4 weeks of a “washout period,” 
over 23 weeks. In addition to the control and single voucher conditions used in Robles et 
al. (2000), Katz et al. (2002) included both a continuous and an interrupted voucher 
schedule, each of which offered reinforcers over more prolonged time periods ($300 
total) compared to Robles et al. (2000). All three experimental conditions produced 
significantly higher rates of abstinence than the control condition; additionally, the 
continuous and interrupted voucher conditions produced higher prolonged rates of 
abstinence than the control and single voucher conditions, neither of which differed in 
abstinence rate by the end of the 11-day experimental period. These results demonstrate 
that a BAT can not only initiate abstinence but that the initial abstinence experience can 
show influence on use in subsequent sessions during which response requirements are 





Sigmon, Correia, and Stitzer (2004) examined the generalizability of repeated 
occurrences of abstinence initiation during a BAT to periods for which no incentives 
were available contingent upon drug abstinence. Their results further demonstrated the 
effectiveness of a BAT for reliably initiating cocaine abstinence among methadone 
patients. Participants in each of two experimental groups provided significantly more 
cocaine-negative urine samples on earning days compared to non-earning days. 
Irons and Correia (2008) extended the application of a BAT to another pattern of 
drug use and to a different population. They used a 3-week ABA-design intervention in 
which 12 college students could earn a substantial monetary reward ($65) contingent on 
providing self-reports indicative of abstinence from smoking and negative urine 
(urinalysis) and breath (CO levels indicative of abstinence) samples of nicotine. 
Participants returned to the lab 1 week following an initial baseline phase for the BAT 
and again 1 week after that for a return to baseline session. Overall, both mean urinalysis 
and CO levels, as well as self-reported measures of abstinence, significantly decreased 
from baseline to the BAT, indicating the generalizability of a BAT to multiple drugs and 
to different populations. However, none of these measures returned to original baseline 
levels at the return to baseline session. Although the causal relation between the BAT and 
change in smoking behavior was confounded by the inconsistent rates of behavior across 
baselines, a failure to return to baseline rates of smoking may represent a clinically 
significant pattern of behavior resulting from the intervention. Being able to initiate 
continued lower levels of drug use is significant from a clinical perspective for which the 





necessary to assess further utility of a BAT as a clinical intervention for initiating (and 
possibly maintaining) drug abstinence. 
The current study  
The purpose of the current study was to examine the potential viability of CM (via 
use of a BAT) for experimentally inducing caffeine abstinence long enough to induce 
peak experience of withdrawal symptoms (i.e., 2 days abstinence) among college 
students. Part of examining the viability of CM for caffeine use includes assessing the 
utility of an ELISA for verifying caffeine use in saliva: The current study therefore 
supplemented self-reports of caffeine use with saliva samples in order to examine the 
potential of verifying behavior with a biological measure. A secondary goal included 
examining the validity of novel measures of caffeine dependence and caffeine 
withdrawal. Based on previous research, I hypothesized that when offered incentives to 
abstain, caffeine consumption would decrease among participants. I also hypothesized 
that experience of caffeine withdrawal symptoms would be greater following abstinence 
relative to following regular consumption. Finally, I hypothesized that scores on a novel 








Inclusion criteria. Participants were 39 undergraduate students (Mage = 19.41, SD 
= 0.94, 74% female, 95% White) enrolled at JMU who were at least 18 years of age, self-
reported consuming at least 25 mg caffeine per day (M = 122.73, SD = 116.08), and who 
did not currently take any prescription medications that contain caffeine during the study. 
A power analysis using G*Power revealed a minimum sample size of 7 to detect an effect 
using the effect size for CM (d = 0.58) obtained by Dutra et al. (2008) with moderate 
power set to .80 for α = .05. 
Recruiting procedures. Participants were recruited from the pool of respondents 
to a central screener that was emailed to the entire student body at James Madison 
University (JMU) during the fall semester. The central screener consists of 21 
questionnaires about various health-related topics. Respondents were invited 40 to 60 at a 
time to participate in an enrollment session during which inclusion criteria were verified. 
During the enrollment session, those respondents that met all inclusion criteria were 
invited to participate in the current study. 
Materials 
 Demographics questionnaire. A demographics questionnaire was used to assess 
demographic information of the participants, including age, gender, and race. 
Daily Caffeine Consumption Questionnaire (DCCQ). This questionnaire was 
used to obtain participants’ self-reported use of caffeine. Three researcher-generated 
items were included to characterize most recent consumption of caffeine. The DCCQ 





to precisely and consistently assess caffeine use among college students by accounting 
for the number of days and servings that an individual consumes various foods and 
beverages containing caffeine. 
 Autonomy Over Caffeine Scale (AUTOC). Currently there is no standard 
measure of dependence for caffeine. The AUTOC measure was adapted from the 
Autonomy Over Smoking Scale (AUTOS; DiFranza et al., 2009) that was developed 
from DSM-IV-TR (APA, 2000) criteria for smoking dependence. The AUTOC includes 
the same 12 items as the AUTOS except wording was altered from tobacco consumption 
to reflect caffeine consumption. The AUTOS is used to assess current tobacco 
withdrawal symptom intensity that represents autonomy, or lack thereof, from nicotine. 
Items are descriptions of experiences of smoking withdrawal symptoms to which the 
participant records how well each describes themselves; responses are recorded on 4-
point Likert scales (0 = not at all, 3 = very well). Scores can range between 0-36, with 
higher scores corresponding to increased experience of withdrawal symptoms, cue-
induced cravings, and psychological dependence. The AUTOS is highly internally 
reliable (α = .91 - .97) and is concurrently valid with Hooked On Nicotine Checklist 
scores (DiFranza et al., 2002) and DSM-IV TR (APA, 2000) diagnostic criteria for 
nicotine dependence. 
Caffeine Withdrawal Scale (CWS). Currently there is no standard measure for 
assessing experience of symptoms of withdrawal from caffeine. This measure was 
adapted from the Wisconsin Smoking Withdrawal Scale (WSWS; Welsh et al., 1999) that 
was developed to assess severity and type of smoking withdrawal symptoms. The CWS 





descriptions of smoking withdrawal symptoms to reflect those of caffeine withdrawal, 
and five items relating to food consumption were removed. Items on the WSWS consist 
of statements related to clinical symptoms of smoking withdrawal (e.g., “I have felt 
impatient”) and are rated on a 5-point Likert-type scale (1 = strongly disagree, 5 = 
strongly agree). The WSWS provides an overall withdrawal score [range = 0 (no 
withdrawal) – 140 (extreme withdrawal)] and scores for each of its 7 subscales, which 
reflect clinical symptoms of nicotine withdrawal: anger, anxiety, sadness, concentration, 
craving, sleep, and hunger (APA, 1994). Internal consistency for measuring overall 
withdrawal is high (α = .90 - .91), whereas subscale internal consistencies are slightly 
lower (α = .75 - .93). Additionally, overall measures on the WSWS are predictive of 
smoking cessation outcomes (Welsch et al., 1999). 
 Stimulant and Caffeine Experience of Withdrawal Symptoms (SCEWS). 
There are currently no standard criteria for measuring symptoms of caffeine withdrawal. 
This measure was created using summaries of symptoms of caffeine withdrawal reported 
by Julien (2008) and McKim (2007), as well as DSM-IV TR criteria for withdrawal from 
small doses of another relatively mild stimulant, amphetamine withdrawal syndrome 
(APA, 2000). Criteria for another stimulant (amphetamine) other than caffeine were used 
because the DSM-IV-TR does not include caffeine withdrawal symptoms. 
 Enzyme-linked immunosorbent assay (ELISA). A caffeine ELISA (Neogen 
Corporation, Lexington, KY) was used to validate self-reported measures of caffeine 
consumption by revealing the presence of caffeine metabolites in saliva samples. After 
samples are obtained, they will be frozen at -40°C until enough samples are collected to 





analyzed at once). Once enough samples have been collected, they are thawed and 
assayed. During an incubation period, samples are placed in dishes pre-coated with 
binding sites. Following incubation the dishes are washed and K-Blue® Substrate is 
added to the dish; the antibodies from the substrate and drug (i.e., caffeine) molecules 
compete for binding sites on the dish. Approximately 30 min after incubation with the 
substrate the samples may be analyzed using a spectrophotometer; color change is 
inversely related with the presence of the drug metabolite in the sample. Results are 
presented as a logarithmic function of light absorbance at 450 nm. 
Design 
The current study was an ABA reversal design. Following enrollment, 
participants experienced a baseline condition. All participants then experienced a BAT 2 
days after the baseline session, followed by a return to baseline 2 to 4 days after the BAT 
session.  
Procedure 
 All sessions occurred between 12:30 p.m. and 6:30 p.m. in a psychology research 
lab. 
 (A) Baseline 1/Enrollment. All participants earned a $10 voucher for attending 
and completing the Baseline 1/enrollment session. This session included verification of 
inclusion criteria (see above) by oral report, followed by informed consent procedures, 
and collection of self-report measures (DCCQ, AUTOC, CWS, and the SCEWS) and a 
saliva sample. Participants were informed that if they returned to the lab 2 days following 
this initial session and demonstrated evidence of abstinence (saliva sample indicative of 





that if they returned to the lab 2 days following this initial session and provided 
biological and self-report measures but failed to demonstrate evidence of abstinence they 
would earn $2. Participants were told that any caffeine use would result in a failed 
biological test. 
(B) Brief Abstinence Test (BAT). Participants returned to the lab 2 days 
following the Baseline 1 session and completed the self-report measures and provided a 
saliva sample. The researcher asked participants if they abstained from caffeine since 
Baseline 1 and then asked probing questions about the experience. Participants who 
demonstrated abstinence were provided a $20 voucher. Participants who did not 
demonstrate abstinence were provided a $2 voucher for attendance. Participants were 
then asked to return to the lab for a return to baseline session for which they could earn 
$5 for attendance, regardless of their caffeine consumption prior to the session, and a $10 
bonus for completing all three sessions with perfect attendance.  
(A) Baseline 2. A final session occurred 2 days following the BAT phase and it 
included completion of the self-report measures and a saliva sample. Participants earned 
$5 for attending the session and a $10 bonus for perfect attendance to all three sessions. 
Participants were able to earn a maximum of $45 if they attended all sessions and 
achieved abstinence criteria during the BAT. The time period for the study for individual 
participants was between 5 to 7 days (Baseline 2 occurred 2 to 4 days after the BAT, 
depending on the day of the week of the BAT). All participant payments were made in 
the form of vouchers until the end of the experiment so that the saliva samples could be 
collectively analyzed using the ELISA. Participants were then instructed to return to the 





to receive cash payment for all sessions in one sum. Research has shown high magnitude 
reinforcers are effective for changing drug use in a CM analog even at delays of 1 week 






Thirty-nine of 42 participants who enrolled completed all three sessions of the 
experiment. One participant withdrew after completing the baseline session and re-
entered later. Analyses excluded data from this participant’s first baseline session as well 
as data from individuals who did not complete all three sessions. Two respondents who 
completed one session did not return for any further sessions and one respondent who 
completed two sessions did not return for the final session; data for these three 
respondents were not used in any analyses. 
Abstinence during the BAT was defined as a verbal self-report of 0 caffeinated 
products consumed since the baseline session supplemented with responses to probing 
questions consistent with experience of withdrawal from caffeine (e.g., “I felt sleepier 
during classes than usual”). Percentage of light transmittance, as measured by the ELISA, 
was used as a supplement to self-reported caffeine for verifying caffeine abstinence. A 
spectrophotometer analyzed all saliva samples in duplicate; as such, values of percentage 
of light transmittance used for statistical analyses were mean values of each pair of 
duplicate samples. In most cases percentage of light transmittance appeared to support 
self-reports, though measurement error (e.g., bad wash during the rinsing process) from 
the ELISA overall was too substantial to be used alone as verification of caffeine 
abstinence. Well readings that seemed to be erroneous (e.g., two samples of one 
replicated sample were notably different) were not excluded in analyses. 
 See Table 1 for a summary of descriptive statistics for the dependent measures. 
See Table 2 for a summary of intercorrelations among the novel measures of caffeine 






Self-report. Among the 39 participants, 37 (95%) met self-report criterion for 
abstinence during the BAT and 18 (46%) during Baseline 2. A repeated-measures 
ANOVA revealed statistically significant differences in self-reported latency (hr) since 
last consuming caffeine, F(1.05, 39.90) = 23.42, p < .001, partial η
2
 = .38. Planned 
contrasts revealed that latency since last consuming caffeine at the BAT (M = 54.23, SD 
= 14.59) and Baseline 2 (M = 49.65, SD = 56.93) sessions were significantly longer than 
for Baseline 1 (M = 7.11, SD = 10.14, ps < .001). Participants who met criteria for 
abstinence did not significantly differ from participants who did not meet criteria for 
abstinence at either BAT or Baseline 2 in terms of self-reported average daily caffeine 
consumption (ps > .05). 
ELISA. Thirty-two of 39 participants (82%) met absolute reduction criterion for 
abstinence during the BAT using self-report and results from the ELISA (i.e., a reduction 
in caffeine use as indicated by the ELISA; no clear cutoff score was evident from the 
analyses nor existed in the literature for caffeine).  
Twenty-four participants (62%) met reduction criterion during the BAT using 
duplicate samples SD (i.e., reduction of ≥ 1 SD for the mean difference between duplicate 
samples across all three sessions). An independent t-test revealed participants who met 
this reduction criterion from Baseline 1 to BAT significantly differed from participants 
who did not meet this criterion in light transmittance during the BAT, t(36.76) = 4.03, p < 
.001, d = 1.20, CI 95% [0.047, 0.142]. Another independent t-test revealed participants 





participants who did not meet this criterion in light transmittance during Baseline 2, t(37) 
= 1.10, p = .280, d = 0.37, CI 95% [-0.032, 0.108]. 
A repeated-measures ANOVA revealed statistically significant differences in light 
transmittance through the saliva samples among the three sessions, F(2, 76) = 8.36, p = 
.001, partial η
2
 = .18. Planned contrasts revealed the BAT (M = 79.58%, SD = 9.23%) 
and Baseline 2 (M = 80.16%, SD = 10.49%) yielded significantly less light transmittance 
compared to Baseline 1 (M = 85.57%, SD = 6.38%, ps = .001 and .005, respectively). 
Neither percentage light transmittance nor latency since last consuming caffeine differed 
significantly between BAT and Baseline 2 sessions (ps = 1.0).  
A median split of self-reported average daily caffeine consumption (median = 90 
mg) yielded high and low caffeine users, neither of which differed in light transmittance 
at Baseline 1, BAT, or Baseline 2 (ps > .05). Participants in the upper and lower quartiles 
of self-reported average daily caffeine use did not significantly differ in light 
transmittance at Baseline 1, BAT, or Baseline 2 (ps > .05). 
Pearson Product-Moment correlations revealed no significant correlations 
between light transmittance and self-reported latency since last consuming caffeine 
during Baseline 1 [r(37) = -.02, p = .882], the BAT [r(37) = -.02, p = .919], or Baseline 2 
[r(37) = -.22, p = .178]. A point-biserial correlation revealed that light transmittance 
significantly negatively correlated with whether or not participants met criteria for 
abstinence from caffeine across all three study sessions such that likelihood of meeting 
criteria for abstinence from caffeine was negatively related with light transmittance, 






 AUTOC. Pearson Product-Moment correlations revealed AUTOC scores and 
CWS scores significantly correlated during Baseline 1 [r(37) = .46, p = .003], the BAT 
[r(37) = .71, p < .001], and Baseline 2 [r(37) = .72, p < .001]. Pearson Product-Moment 
correlations also revealed AUTOC scores and SCEWS scores significantly correlated 
during Baseline 1 [r(37) = .37, p = .020], the BAT [r(37) = .75, p < .001], and Baseline 2 
[r(37) = .64, p < .001]. 
A repeated-measures ANOVA revealed that AUTOC scores significantly differed during 
the three study sessions, F(1.66, 63.23) = 5.27, p = .011, partial η
2
 = .122. Planned 
contrasts showed AUTOC scores increased significantly from Baseline 1 (M = 8.72, SD = 
5.99) to BAT (M = 10.62, SD = 8.77, p = .023), and declined slightly from BAT to 
Baseline 2 (M = 10.28, 8.46, p = 1.0). AUTOC scores did not differ significantly between 
Baseline 1 and Baseline 2 (p = .098).  
Pearson Moment-Product correlations revealed AUTOC scores and percentage 
light transmittance were significantly negatively correlated during each Baseline 1 [r(37) 
= -.34, p = .032] and Baseline 2 [r(37) = -.42, p = .008], but were not significantly 
correlated during the BAT [r(37) = -.11, p = .502]. Additionally, Baseline 1 AUTOC 
scores were not significantly related with self-reported average daily caffeine 
consumption, r(37) = .05, p = .802. Using a median split of self-reported average daily 
caffeine consumption, high and low caffeine users did not significantly differ in AUTOC 






 Pearson Product-Moment correlations revealed CWS and SCEWS scores 
significantly correlated during Baseline 1 [r(37) = .36, p = .024], the BAT [r(37) = .67, p 
< .001], and Baseline 2 [r(37) = .58, p < .001]. 
CWS. A repeated-measures ANOVA revealed that CWS scores did not 
significantly differ across the three study sessions, F(2, 76) = 0.56, p = .576, partial η
2
 = 
.014. CWS scores slightly increased from Baseline 1 (M = 64.38, SD = 6.77) to BAT 
(M = 65.26, SD = 8.82) and declined slightly from BAT to Baseline 2 (M = 65.15, 8.98), 
though not back to Baseline 1 levels. 
Using a median split of self-reported average daily caffeine consumption, high 
and low caffeine users did not significantly differ in CWS scores at BAT or Baseline 2 
(ps > .05).  
Independent t-tests revealed participants who met reduction criterion from 
Baseline 1 to BAT using duplicate samples SD significantly differed in CWS scores from 
participants who did not meet this criterion during the BAT, t(37) = 2.76, p = .009, d = 
0.93, CI 95% [1.95, 12.81], and likewise from BAT to Baseline 2 during Baseline 2, t(37) 
= 3.21, p = .003, d = 1.12, CI 95% [3.23, 14.31]. 
Pearson Moment-Product correlations revealed CWS scores and percentage light 
transmittance were not significantly correlated during Baseline 1 [r(37) = -.10, p = .546] 
or the BAT [r(37) = .129, p = .435], but were significantly negatively correlated during 
Baseline 2 [r(37) = -.33, p = .038].  
SCEWS. A repeated-measures ANOVA revealed that SCEWS scores 







= .153. Scores on the SCEWS significantly increased from Baseline 1 (M = 3.05, SD = 
3.04) to BAT (M = 5.00, SD = 4.48, p = .010) and significantly declined from BAT to 
return to baseline (M = 2.97, SD = 3.96, p = .012). SCEWS scores did not differ across 
the two baseline sessions (p = 1.0). 
Using a median split of self-reported average daily caffeine consumption, high 
and low caffeine users did not significantly differ in SCEWS scores at BAT or Baseline 2 
(ps > .05). 
Independent t-tests revealed participants who met reduction criterion from 
Baseline 1 to BAT using duplicate samples SD did not significantly differ in SCEWS 
scores from participants who did not meet this criterion during the BAT, t(37) = 1.03, p = 
.310, d = 0.35, CI 95% [-1.47, 4.50], but SCEWS scores did significantly differ between 
these groups from BAT to Baseline 2 during Baseline 2, t(13.71) = 2.64, p = .020, d = 
1.20, CI 95% [1.67, 6.48]. 
Pearson Moment-Product correlations revealed SCEWS scores and percentage 
light transmittance were not significantly correlated during Baseline 1 [r(37) = -.19, p = 
.248] or the BAT [r(37) = -.02, p = .895], but were significantly negatively correlated 






The current study examined the potential efficacy of CM for initiating caffeine 
abstinence among college students of varying levels of typical caffeine consumption 
using a BAT, and to induce abstinence from caffeine long enough for participants to 
experience peak withdrawal symptoms so that novel measures of caffeine withdrawal and 
dependence could be examined. Results indicated the BAT was effective for initiating 
abstinence from caffeine among participants. A majority of participants (95%) met 
criteria for abstinence from caffeine when offered a high magnitude monetary incentive, 
and nearly half of all participants continued to abstain from caffeine at the return to 
baseline session. Scores on the novel measure of caffeine dependence, the AUTOC, 
unexpectedly varied across sessions contrary to what would be expected of levels of 
dependence over the course of approximately 1 week. AUTOC scores were not related to 
baseline levels of caffeine consumption. Scores on one novel measure of caffeine 
withdrawal, the CWS, did not systematically vary across sessions as predicted based on 
the apparent success of the BAT for initiating abstinence from caffeine and thus inducing 
withdrawal; however, scores on the other novel measure of caffeine withdrawal, the 
SCEWS, did vary across sessions as predicted. SCEWS scores differed across sessions as 
a function of whether participants met criteria for abstinence from caffeine whereas CWS 
scores did not. 
Aggregated results from an ELISA matched aggregated self-reported levels of 
abstinence throughout the study, though results for individual samples sometimes varied 
nonsystematically from self-reports. The use of an ELISA for providing a biological 





which only used self-report measures to verify caffeine use (e.g., Foxx & Rubinoff, 
1979); however, because individual data from the ELISA were sometimes incongruent 
with self-reports it is unclear how well this technology measures caffeine use for the 
purposes of the current research design. Results of the ELISA were moderately 
inconsistent within and between samples. Individual factors (e.g., metabolic rate, caffeine 
use prior to experimental time periods) possibly influenced ELISA results, though how 
and to what degree are not clear and warrant further research. As such, ELISA results 
themselves were not sufficient as a criterion for determining caffeine use in the current 
study. Further research is warranted to examine exactly how these factors influence the 
ELISA so that criterion values or percent change may be established to discern caffeine 
abstinence over a certain period of time. Additionally, future research on caffeine 
consumption would benefit from advances in technology for determining levels of 
caffeine use similar to simple techniques available for smoking (e.g., urinalysis), alcohol 
(e.g., breathalyzer), and other drugs. Such a technology would not only aid in caffeine 
research but could also be used as a medical tool for screening caffeine consumption as a 
potential contributing factor for numerous health-related problems (e.g., anxiety 
symptoms, insomnia, or headaches for which there is no clear underlying cause).  
 Caffeine consumption reduced during the BAT but did not increase to baseline 
levels during the return to baseline. Although this is a challenge to inferring a causal 
relation, it is a clinically preferred outcome relative to observing a complete return to 
baseline levels of behavior and one that has been reported using a BAT in the literature 
(Irons & Correia, 2008). That is, to observe the success of the BAT coupled with the 





clinical setting would likely be considered a success. Because no participants met criteria 
for abstinence at baseline and 95% of participants met criteria for abstinence during the 
BAT, it is unlikely that the phase changes did not exert experimental control. Despite the 
apparent effectiveness of the intervention, the lack of a return to baseline levels of 
behavior confounds a causal relation between the BAT and the change in caffeine 
consumption. Participants may have continued to remain abstinent from caffeine because 
they encountered the appetitive effects of abstinence such as the cessation of experience 
of withdrawal symptoms. Future research on the BAT could use multiple baseline 
designs or between-subjects designs to discern the apparent causal relation between the 
BAT and changes in caffeine consumption. 
If participants continued to abstain from caffeine use due to encountering the 
appetitive effects of abstinence then a BAT may be an effective but also sufficient 
treatment method for reducing caffeine consumption. Unlike other drugs (e.g., nicotine) 
cue-induced relapse for caffeine use is likely not an important post-intervention risk. 
Although past researchers (e.g., James, Stirling, & Hampton, 1985) suggested treatment 
for reducing caffeine use should fading components to avoid initiating aversive 
withdrawal symptoms, the observed results indicate that a single contingency is sufficient 
for initiating reduced caffeine consumption. Thus a BAT may be a more cost-effective 
treatment option for problematic caffeine consumption than a fading procedure or a large-
scale CM intervention. However, the long-term implications of reduced caffeine use 
among individuals for whom caffeine consumption is problematic are not clear. Given 





term benefits of reduced caffeine use would be less than the cost of implementing BATs 
to induce the change in consumption. 
Participants did not receive payment until 2 to 6 days following their final session. 
Delay of delivery of contingencies did not appear to influence behavior to a greater 
degree than did the experimental design. These results are consistent with those of 
Packer, Howell, McPherson, and Roll (2012), who found that high magnitude reinforcers 
can cause reduced drug use even when delivered at delays of up to 1 week. Two 
participants did not meet criteria for caffeine abstinence during the BAT. One participant 
reported that they forgot about the instructions given during Baseline 1. The other 
participant who did not abstain from caffeine during the BAT reported they “needed 
caffeine” because they had a test the morning of the day of the BAT session. Despite the 
fact that these observed limitations were beyond experimental control, the intervention 
achieved the primary goal of the study as evident by the majority of the sample who met 
criteria for abstinence from caffeine. Future research on CM of caffeine consumption 
could control for these specific issues by manipulating saliency of the contingencies (e.g., 
sending verbal reminders via text message or E-mail). 
 The novel measure of caffeine dependence and one of the novel measures of 
withdrawal (CWS) were developed from analogous measures for smoking. No such 
measures exist for caffeine; smoking measures were adapted for caffeine because 
caffeine consumption is moderately analogous to cigarette smoking (legal, occurs over 
the course of the day, effects are relatively mild, CM works for both). AUTOC scores 
differed across experimental phases contrary to what would be expected of drug 





2009). Additionally, baseline AUTOC scores were not significantly related to self-
reported average daily caffeine consumption contrary to what would be expected based 
on previous attempts to measure caffeine dependence (Hughes et al., 1998; it is important 
to note here that self-reported average daily caffeine consumption did not appear to vary 
meaningfully in any statistical analyses using any variables in the current study). Thus the 
AUTOC either does not effectively measure caffeine dependence or caffeine dependence 
may change rapidly relative to dependence for other drugs such as nicotine (DiFranza et 
al., 2009). Given the sparse literature on measuring dependence for caffeine further 
research is necessary to define the construct. Stronger validity evidence may be gathered 
for the AUTOC once the construct of interest is more clearly defined. Additionally, the 
AUTOC may be adapted to more validly measure caffeine dependence: Items on the 
AUTOC were derived from a measure of smoking dependence, a construct that may not 
be as similar to caffeine dependence as originally hypothesized. 
 The majority of participants met criteria for abstinence during the BAT, which 
allowed for caffeine withdrawal to be examined. CWS scores did not differ across 
sessions as would be expected given the majority of participants experienced abstinence 
(and thus withdrawal) at least once during the study. As predicted, SCEWS scores 
significantly differed during the BAT when experience of abstinence was greatest among 
the sample. However, CWS and SCEWS scores significantly correlated at all three time 
points. The CWS was derived from a measure of smoking withdrawal that assessed 
responses to experience of symptoms of withdrawal on a 5-point Likert scale. The 
SCEWS was derived from lists of common symptoms of caffeine withdrawal in two 





experiencing the symptoms. Interestingly, CWS scores significantly differed at both the 
BAT and return to baseline between participants who reduced and did not reduce caffeine 
use as evident by reduction of light transmittance by at least one SD derived from 
duplicated saliva samples across all three sessions. SCEWS scores only significantly 
differed at Baseline 2. It is conceivable that both the CWS and the SCEWS measure 
experience of caffeine withdrawal to varying degrees such that the SCEWS may provide 
more valid responses than the CWS. The current study provides preliminary evidence for 
the utility of the CWS, and SCEWS; however, further validity evidence is necessary (e.g., 
using large sample sizes than the one used in the current study) before either the CWS or 
the SCEWS may be used for clinical purposes. 
It is important to develop sound measures of caffeine dependence and withdrawal 
so that these constructs may be validly and reliably measured. Despite previous attempts 
to characterize these constructs (Hughes et al., 1998; Juliano & Griffiths, 2004), currently 
no such measures exist for caffeine dependence or withdrawal. Thus it is difficult to 
determine the extent and severity of these phenomena. Likewise the potential utility of a 
BAT may be fully realized only after problematic caffeine consumption (e.g., incidences 
of caffeine dependence) is better characterized in order to identify individuals for whom 
treatment would be beneficial. Additionally, valid measures of caffeine dependence and 
withdrawal would allow for caffeine to serve as a model for studying dependence and 
withdrawal phenomena in other drugs. 
 Given the promising results observed in the current study, future research should 
examine CM of caffeine over a longer time period. Because caffeine consumption can be 





reinforcing continued abstinence from caffeine beyond experience of peak withdrawal 
symptoms, although the current results indicate such generalization of treatment 
outcomes may supersede the need for continued reinforced abstinence. Long-term 
compliance with the dietary changes associated with reduced caffeine use may be 
optimally pursued through such methods (Griffiths & Reissig, 2008). Additionally, the 
overall success observed in the current study using a sample of users of a wide range of 
caffeine suggests similar research may be fruitful among other populations of interest 
(e.g., users of high levels of caffeine, users advised to avoid caffeine). Specific aspects of 
the BAT (e.g., payment amount) could be manipulated to determine optimally cost-
effective conditions for implementing CM for caffeine. 
The current study showed caffeine use can be experimentally manipulated by a 
CM procedure similarly to how many other drugs have been shown to do (e.g., alcohol, 
Miller et al., 1974). These results indicate CM may be a viable avenue for treating 
problematic caffeine consumption. Novel measures of caffeine dependence and 
withdrawal provide a preliminary attempt to assess these phenomena. It is hopeful that 
further research on treatment of caffeine consumption will allow for the measurement of 
caffeine dependence and withdrawal so that individuals who need treatment may be 






Descriptive Statistics for Dependent Measures 
 Baseline 1 BAT Baseline 2 
 M SD M SD M SD 
Caffeine Latency (hr)  7.11 10.14 54.23 14.59 49.65 56.93 
% Light Transmittance 85.57 6.38 79.58 9.23 80.16 10.49 
AUTOC 8.72 5.99 10.62 8.77 10.28 8.46 
CWS 64.38 6.77 65.26 8.82 65.15 8.98 
SCEWS 3.05 3.04 5.00 4.48 2.97 3.96 
Note. N = 39. Caffeine Latency (hr) = self-reported latency since last consuming caffeine in 
hours. AUTOC scores can range from 0 to 36 with higher scores indicative of greater caffeine 







Summary of Intercorrelations for AUTOC, CWS, and SCEWS 
Measure 1 2 3 4 5 6 7 8 9 
1. AUTOC1  –         
2. AUTOC2  .91** –        
3. AUTOC3  .87** .94** –       
4. CWS 1 .46** .52** .60** –      
5. CWS 2 .56** .71** .77** .75** –     
6. CWS 3 .52** .59** .72** .73** .85** –    
7. SCEWS 1 .37* .25 .34* .36* .29 .37* –   
8. SCEWS 2 .67** .75** .78** .38* .67** .60** .52** –  
9. SCEWS 3 .57** .50** .64** .50* .40* .58** .51** .52** – 
Note. Intercorrelations for novel measures of caffeine dependence and withdrawal (N = 39) at 
Baseline 1(1), BAT (2), and Baseline 2 (3). 







Figure 1. Percentage of light transmittance at 450 nm. Lower levels of transmittance are 








































Figure 2. Number of participants who met criteria for abstinence during each study 
phase. No participants met criteria during Baseline 1, 37 participants met criteria during 










































Contingency Management of Caffeine Consumption Cessation (IRB#12-0199) 
 
You may be eligible to participate in a study on caffeine consumption behavior. This study 
is being conducted Dr. Jessica Irons, an assistant professor of psychology at James 
Madison University along with Brad Joachim, a graduate student in psychology.  Your 
responses to a recent web-based survey indicate that you are a student at James Madison 
University and you consume at least 25 mg caffeine per day. If either of these is incorrect, 
please tell the researcher at this time.   
 
Participation in this study is voluntary. If you decide to participate, you will sign this 
informed consent form. Please ask any questions before you sign. If you choose to 
participate in this study, you will complete several questionnaires and answer some 
questions about your caffeine consumption today. You will also be asked to provide a 
saliva sample, which is necessary to verify that your caffeine consumption level meets a 
required level to participate in this study. This intake session will take approximately 20 
minutes of your time, and you will be compensated for your participation with monetary 
payment ($10).  
 
The remainder of the study will last approximately 1 week. During the remainder of the 
study you will be asked to attend the lab two more times in addition to today. During each 
of these visits, you will be asked to provide a saliva sample and to complete a brief self-
report measure. Each of these visits will take approximately 15 minutes and will not exceed 
30 minutes.  Depending on the session, you may earn access to money depending on your 
caffeine consumption behavior; however, you do NOT have to change your caffeine 
consumption behavior to be enrolled in this study or to earn money in this study (i.e., you 
may earn some money regardless of your caffeine consumption).  
 
You will be compensated for your participation with monetary payment.  Payments will be 
made in lump sum following sample analysis, which will occur 1 – 3 days after the last 
session of the study. Payment amounts will vary by session. In total, you may be able to 
earn up to $45.00 over the course of the study. You will be compensated for attendance, 
regardless of your caffeine consumption behavior. You are NOT required to change your 
caffeine consumption behavior to participate in this study. If you choose to change your 
caffeine consumption behavior, you may earn access to payment as a result. In the event 
that you miss one scheduled session, you will be contacted to reschedule an appointment. 
Should you miss more than two appointments throughout the study, you will be removed 
from the study. 
 
All responses will be confidential, and to maintain your privacy, your questionnaires will 
be labeled by a code number that we assign to you. Your name will not be linked to your 
data in any way. The master code list will be kept in a locked filing cabinet separate from 
the data that is accessible only to the researcher.  The master code list will be destroyed 






The risks of participating in this intake session are minimal. You may find answering 
questions about your use of caffeine distressing.  Abstinence from caffeine consumption 
may be associated with mild symptoms such as headache, drowsiness, fatigue, irritability, 
or negative mood state. Breaches of confidentiality are highly unlikely because your 
identifying information will be kept separately from the questionnaires that you complete, 
and your questionnaires will be identified by your code number. You have the option to 
withdraw your consent to participate at any point of this session.  If you decide to withdraw 
from the study you will not be penalized.  
 
The direct benefit to you, the participant, is the opportunity to qualify for a study in 
which you will have the opportunity to engage in brief caffeine consumption abstinence, 
and you may be able to use the study as a way of initiating longer term caffeine 
consumption abstinence. Potential to engage in brief substance is predictive of successful 
longer term abstinence in the future. We cannot promise you that you will achieve either 
short- or long-term abstinence from caffeine consumption. Your participation has the 
potential to benefit the public by helping psychologists develop better methods of 
substance use cessation.  
 
Information collected through your participation may be published in a professional 
journal, and/or presented at a professional psychology conference.  However, your name 
and any other identifying information will not be associated with the data collected, and 
you will thus remain confidential.   
_____ Participant’s Initials 
 
Your decision whether or not to participate will not jeopardize your future relations with 
James Madison University, or the Department of Psychology.  If you have any further 
questions or would like to receive a copy of the final aggregate results of this study, 
please contact Dr. Jessica Irons (568-6565, ironsjg@jmu.edu, Department of 
Psychology).  
 
For more information regarding your rights as a research participant you may contact the 
James Madison University IRB Chair, Dr. David Cockley (540-568-2834, 
cocklede@jmu.edu).     
 
HAVING READ THE INFORMATION PROVIDED YOU MUST DECIDE WHETHER 
OR NOT YOU WISH TO PARTICIPATE IN THIS INTAKE SESSION. YOUR 
SIGNATURE INDICATES YOUR WILLINGNESS TO PARTICIPATE. 
 
By signing this form, I certify that I am at least 18 years of age. 
 
________________________________          ____________________________ 
Participant's signature                     Date          Investigator's signature   Date 
 
________________________________          ____________________________ 








Please answer the following questions as completely as you can to the best of your 
ability. 
  
Gender:      Female          Male      
Age:               years    
Race:   (select all that apply)  
  Asian  
      Black or African American  
      White  
      Hispanic or Latino  
      American Indian or Alaska Native  
      Native Hawaiian or Other Pacific Islander  
      Multi-ethnic  
      Other 
 




How regularly do you smoke (answer in days per week)? 
__________ 
 
Do you suffer from any cardiovascular health problems? 
Yes ______ No ______ 
 
Do you suffer from any medical conditions? 
Yes ______ No ______ 
 
Do you have any diagnosed psychological/psychiatric conditions? 
Yes ______ No ______ 
 
Do you currently take any prescription medications (please do not include birth 
control when answering this question)? 
Yes ______ No ______ 
 
Do you take any recreational drugs other than alcohol or nicotine? 
Yes ______ No ______ 
 
Are you currently pregnant or attempting to get pregnant? 
Yes ______ No ______ 
 





__________ days per week 
 
Are you particularly sensitive or allergic to the effects of caffeine? 
Yes ______ No ______ 
 
Have you ever been advised to avoid caffeine? 
Yes ______ No ______ 
 
What is your height (report in inches)? 
__________ inches 
 
What is your weight? 
__________ lbs. 
 
Please indicate how stressful you feel your daily life is on average (scale of 1-10, 1 = 




On average, how much expendable money (i.e., money that you can spend for 




Are you willing to be contacted about opportunities to participate in future studies 
about caffeine consumption where you would have the opportunity to earn money 
or gift certificates and coupons? ____ Yes        _____ No 
 
If yes, are you willing to provide biological samples to verify your level of caffeine 
consumption? These measures will be used ONLY to assess caffeine consumption 







Daily Caffeine Consumption Questionnaire (DCCQ) 
 
What is your most consumed source of caffeine? (e.g., coffee, tea, soft drinks, energy 
drinks, chocolate, caffeinated gum) 
____________________________________ 
 
How long has it been since you last consumed a caffeinated product? 
____________________________________ 
 
How much caffeine did you consume then? (e.g., 2 cups of coffee, a 20 oz. bottle of soda, 








Autonomy Over Caffeine Scale (AUTOC) 
 










1. When I go too long without a caffeinated product, I get impatient.     
2. When I got too long without a caffeinated product, I get strong urges that are hard to get rid of.     
3. When I go too long without a caffeinated product, I lose my temper more easily.     
4. When I go too long without a caffeinated product, I get nervous or anxious.     
5. I rely on caffeinated products to focus my attention.     
6. I rely on caffeinated products to take my mind off being bored.     
7. I rely on caffeinated products to deal with stress.     
8. I would go crazy if i couldn't have a caffeinated product.     
9. When I feel stressed, I want a caffeinated product.     
10. When I see other people consuming caffeinated products, I want to do so as well.     
11. When I smell a caffeinated product, I want to consume a caffeinated product.     








Caffeine Withdrawal Scale 
 
 
Please answer the following questions based on how you 
have felt or what you have noticed [over the last 24 
hours/over the last week]. Answer based on how you have 










1. I am getting restful sleep      
2. I have been tense or anxious.      
3. My level of concentration is excellent      
4. I awaken from sleep frequently during the night.      
5. I have felt impatient.      
6. I have felt upbeat and optimistic.      
7. I have found myself worrying about my problems.      
8. I have had frequent urges to consume caffeinated 
products. 
     
9. I have felt calm lately.      
10. I have been bothered by the desire to consume 
caffeinated products. 
     
11. I have felt sad or depressed.      
12. I have been irritable, easily angered.      
13. I have been bothered by negative moods such as anger, 
frustration, and irritability. 
     
14. I am satisfied with my sleep.      
15. I have felt frustrated.      
16. I have felt hopeless or discouraged.      
17. I have thought about consuming caffeinated products a 
lot. 
     
18. I feel that I am getting enough sleep.      
19. It is hard to pay attention to things.      
20. I have felt happy and content.      
21. My sleep has been troubled      
22. I have trouble getting caffeinated products off my mind.      








Stimulant and Caffeine Experience of Withdrawal Symptoms 
 
Indicate whether you have recently (i.e., in the previous couple hours) 
experienced the following more so than you normally may experience each: 
Yes No 
1. Headache   
2. drowsiness   
3. fatigue   
4. negative mood state   
5. impaired intellectual performance   
6. impaired motor performance   
7. difficulty with concentration   
8. decreased energy   
9. weakness   
10. lethargy   
11. decreased motivation for work   
12. impaired concentration   
13. increased irritability   
14. flu-like symptoms (aches, muscle stiffness, hot/cold spells, nausea, 
heavy feelings in the limbs) 
  
15. vivid, unpleasant dreams   
16. insomnia or hypersomnia   
17. increased appetite   
18. psychomotor retardation or agitation   
19. experience of one of the above has caused significant distress or 











The purpose of this study was to examine an intervention designed to help individuals 
reduce their caffeine consumption. If participation in this study caused you any 
discomfort or distress, you should visit one of the following: 
 
o Your personal general practitioner. 
o University Health Center located next to Burruss Hall, at the corner of Mason and 
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